This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Academic Highlights

Atypical Antipsychotic Agents in the Treatment of Schizophrenia and Other Psychiatric Disorders. Part I: Unique Patient Populations

Stephen R. Marder, M.D.; Dilip V. Jeste, M.D.; and Joseph P. McEvoy, M.D.

Published: May 15, 1998

Article Abstract

Click to enlarge page

A large proportion of patients with schizophrenia fail to respond adequately to their medications and can be considered as treatment-refractory, Dr. Stephen R. Marder declared. The advent of newer atypical antipsychotics requires an expanded definition of treatment refractoriness and more thoughtful application of treatment alternatives to the traditional dopamine receptor antagonists. In this context, Dr. Marder discussed positive symptoms and broadened the definition of patients who could be considered treatment- refractory.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 59

Quick Links: Psychotic Disorders , Schizophrenia and Schizoaffective Disorders

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...